Costs of managing severe immune ...
This study aims to report resource utilisation and annual cost for chronic immune thrombocytopenia (ITP) patients enrolled consecutively and followe ...
Efficacy of the combination of ...
Bortezomib–dexamethasone (Btz/Dex) is an active regimen in patients with multiple myeloma and has been used in few patients with amyloidosis. Here, ...
Pilot study of pegylated interf ...
The role of the Epstein–Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemothera ...
The metalloprotease, NN-PF3 fro ...
NN-PF3 is a non-toxic, anticoagulant, highmolecular- mass (67.81 kDa) metalloprotease from Indian cobra (Naja naja) venom. In the present study, NN- ...
Proteasome inhibitor bortezomib ...
Endothelial cells have special relevance in tumor progression. Here, we investigated the effect of the proteasome inhibitor bortezomib on tumor–endo ...
Lenalidomide in combination wit ...
Over the past decade, treatment options for patients with multiple myeloma (MM) have improved substantially, resulting in better response rates and ...
Long-term outcomes of HLA-match ...
Allogeneic hematopoetic stem cell transplantation (allo-HSCT) remains the only curative therapy for chronic myelogenous leukemia (CML). In this stud ...
A modified regimen of pegylated ...
Preclinical and clinical studies have demonstrated synergy between bortezomib and pegylated liposomal doxorubicin (PLD) for relapsed/refractory (R/ ...
Gemcitabine and vinorelbine com ...
We investigated the efficacy of gemcitabine and vinorelbine (Gem/Vin) combination chemotherapy as a salvage and mobilization regimen in relapsed or ...
Hematopoietic stem cell mobiliz ...
Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 ...
Characteristics of BCR–ABL kina ...
To explore the characteristics of BCR–ABL kinase domain point mutations in Chinese chronic myeloid leukemia (CML) patients, a cohort of 127 patients ...
Prognostic factor analyses of m ...
Multiple myeloma (MM) survival plots usually display steeper initial and shallower subsequent slopes reflecting differences in disease biology and l ...
Phase II fludarabine and cyclop ...
Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have ...
A study on nm23-H1 expression i ...
In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significant ...
Limited role of interim PET/CT ...
Positron emission tomography (PET) has been found useful in monitoring response to treatment of malignant lymphoma. We investigated the ability of ...
The importance of a sub-region ...
The gene RAI was originally described as an inhibitor of RelA/p65 subunit of nuclear factor ƒبB (NF.ƒبB). Here, we analyse the association between g ...
CXCR4 expression on transplante ...
Expression of the chemokine receptor CXCR4 by haematopoietic stem cells (HSCs) is believed to influence the process of these cells پehomingپf back t ...
Seven-year response to imatinib ...
The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment in Chinese patients with ...
Random skin biopsy and bone mar ...
Intravascular lymphoma (IVL) is a rare type of extranodal lymphoma in which the lymphoma cells proliferate exclusively in the lumina of small vessel ...
Hypoxia-inducible factors in ma ...
Aberrant activation of phosphoinositide-3 kinase/ Akt (PI3K/Akt) and mammalian target of rapamycin (mTOR) signaling is implicated in the pathogenesi ...
Resveratrol increases rate of a ...
In this study, we attempted to assess the interactions of resveratrol, a natural compound present in various plant species, with the purine analogue ...
Primary bone marrow diffuse lar ...
Diffuse large cell lymphoma involving bone marrow is not uncommon, but primary, de novo, bone marrow diffuse large B cell lymphoma (DLBCL) is rare. ...
Secondary central nervous syste ...
Secondary central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL) includes an isolated CNS relapse or CNS involvement with ...
Indoleamine 2,3-dioxygenase in ...
Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO ...
Thrombospondin-1 (TSP-1) in pri ...
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm showing aberrant bone marrow remodeling with increased angiogenesis, progressiv ...